The 17 members of the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee who voted 17-0 in favor of authorizing Pfizer’s COVID vaccine for kids ages 5 to 11 all have deep ties to pharma.
On Oct. 26, the membership of the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 17-0 in favor of lower-dose use of Pfizer’s experimental COVID-19 vaccine in children ages 5 to 11.
The 17 individuals — including an “acting” committee chair and 11 voting members who were temporary rather than core VRBPAC members — formulaically stated the injections’ benefits outweigh the risks in that age group.
Three days later, Dr. Janet Woodcock — a 35-year FDA veteran serving “temporarily” as commissioner — evoked her personal credentials “as a mother and a physician” when she predictably extended Pfizer’s emergency use authorization (EUA) to the 5-11 age group, having previously granted EUAs for adolescents (ages 12-15) and those age 16 and up.
This article highlights the conflicts of interest and financial entanglements with vaccine companies that enabled this rogues’ gallery’s immoral vote to expose 28 million U.S. children to the risk of injury and death.
These conflicts are ably documented by groups such as the Project On Government Oversight (POGO), in databases such as the Centers for Medicare & Medicaid Services’ Open Payments and in the Children’s Health Defense (CHD) eBook, “Conflicts of Interest Undermine Children’s Health.”
Read More: 17 Pharma Henchmen Who Voted to Experiment on Your Kids
